ABSTRACT
Mpox, endemic to Central and West Africa, has recently seen a rise in cases in non-endemic regions, emphasizing the need for specific vaccines. The Mpox virus (MPXV) produces two infectious virions: intracellular mature virions (IMvs) and extracellular enveloped virions (EEvs). IMVs mediate host-to-host transmission, while EEvs facilitate viral dissemination within tissues. This study aimed to develop and evaluate recombinant protein-based vaccine formulations targeting MPXV A29L (IMV), A30L (IMV), and A35R (EEV) proteins to enhance immune responses. Four alum-adjuvanted recombinant protein vaccine formulations containing A29L, A30L and A35R antigens were developed based on the high sequence homology of MPXV with variola and vaccinia viruses. The vaccines were formulated with an alum adjuvant and administered to BALB/c mice. Antigen-specific immune responses were assessed by measuring IgG titers and analyzing cytokine expression profiles to determine the polarization of Th1/Th2 cells. The vaccine formulations induced significant increases in antigen-specific IgG titers in immunized BALB/c mice, with the trivalent A29L+A30L+A35R formulation eliciting the highest overall antigen-specific IgG response. Cytokine expression analysis indicated a predominantly Th2-biased immune response. These findings demonstrate the immunogenicity of A29L, A30L, and A35R proteins when combined with an alum adjuvant and provide an immunogenicity proof-of-concept for their further evaluation as recombinant protein-based MPXV vaccine antigens.
KEYWORDS: Mpox, subunit vaccine, recombinant protein, Orthopoxvirus, alum, immune response
Introduction
Mpox is a zoonotic disease caused by monkeypox virus (MPXV), a double-stranded DNA virus belonging to the genus Orthopoxvirus within the family Poxviridae. The Orthopoxvirus genus also includes variola virus (VARV), vaccinia virus (VACV), and cowpox virus (CPXV), all of which share considerable genetic and antigenic similarity. MPXV is a naturally occurring wildlife virus that can cause a systemic disease in humans, manifesting as a widespread rash.1
Since its discovery, MPXV has been endemic to parts of West and Central Africa. However, in May 2022, the first confirmed case outside Africa was reported in the United Kingdom in a patient who had traveled from Nigeria, marking the beginning of a multi-country outbreak. This initial case was not immediately linked to sustained local transmission from an endemic area.2–4 As of June 2024, nearly 100,000 confirmed cases and over 200 deaths have been reported globally, according to the WHO’s “Mpox Global Strategic Preparedness and Response Plan (SPRP 2024),” which states that the multi-country outbreak has resulted in such numbers.5 The WHO declared mpox a Public Health Emergency of International Concern (PHEIC) on 14 August 2024 and subsequently published the SPRP, which includes recommendations for targeted preventive vaccination in regions with high case burdens and among high-risk groups, such as healthcare workers.6 There is currently no licensed or WHO-prequalified vaccine developed specifically for mpox, which underscores the urgent need for continued vaccine research. Several smallpox vaccines, including MVA-BN (Imvamune®/Imvanex®/Jynneos®), LC16m8, and ACAM2000, are under consideration for use against mpox.7–9 According to WHO, these vaccines can be administered both as pre-exposure prophylaxis for high-risk groups (such as healthcare workers and close contacts) and as post-exposure prophylaxis, ideally within the first 4 days after exposure and up to 14 days if symptoms have not developed. However, WHO does not recommend mass vaccination and emphasizes that immunization should complement other public health measures such as surveillance, early detection, isolation, and contact tracing. Importantly, there are still limited data on whether these vaccines are sufficient to prevent sustained transmission. Therefore, the development of a universal mpox-specific vaccine remains imperative to ensure preparedness for future unforeseen epidemics and pandemics.10 MPXV is transmitted mainly through close contact with infected individuals or contaminated materials, and typical symptoms include fever, lymphadenopathy, and a characteristic rash.11–13 Two infectious forms of the virus, the intracellular mature virion (IMV) and the extracellular enveloped virion (EEV), play distinct roles in transmission and viral dissemination. Antibodies against these viral forms are therefore considered critical for protection, highlighting the importance of vaccine strategies that can induce effective humoral immunity.14,15
The monkeypox virus has 90% genomic homology with the human smallpox virus (VARV). Much of the current knowledge regarding immune responses to MPXV is derived from studies of VACV because MPXV and VACV share approximately 92% nucleotide and 88% protein sequence similarity.16 In studies conducted with VARV, IMV proteins, A27L, L1R, H3L, and D8L proteins, as well as EEV proteins A33R and B5R, are thought to be associated with immunogenicity. Homologous proteins in MPXV are A29L, M1R, H3L, E8L, A35R and B6R, respectively.17 In addition, the variola virus (VARV) A31L protein and its homolog, A28L in vaccinia virus (VACV), have been investigated as targets involved in viral entry, cell-to-cell fusion, and neutralizing antibody responses. The corresponding homolog in MPXV is A30L.18 Compared with A29L and A35R, A30L has been less extensively investigated as a vaccine antigen despite its reported role in viral entry and membrane fusion.
Therefore, the present study aimed to develop recombinant protein-based subunit vaccine formulations containing the MPXV antigens A29L, A30L, and A35R and to evaluate their immunogenicity in a murine model.
Materials and methods
Development and characterization of vaccine formulation
Preparation of vaccine formulations
Aluminum hydroxide gel (InvivoGen, San Diego, CA, USA; Cat. No. vac-alu-50) was used as an adjuvant to prepare vaccine formulations containing recombinant MPXV A29L, A30L, and A35R proteins. The formulations were gently mixed at room temperature to achieve a total antigen concentration of 40 µg/mL and an alum concentration of 2 mg/mL. In the trivalent A29L+A30L+A35R formulation, the three antigens were combined at an equal mass ratio (1:1:1), corresponding to approximately 13.33 µg/mL of each antigen.
Characterization of vaccine formulations
The total protein concentration of the vaccine formulations was determined using the Bicinchoninic Acid (BCA) assay. The alum-adsorbed protein in the formulations was precipitated by centrifugation at 1000 rpm for 5 min, and the amount of free (non-adsorbed) protein remaining in the supernatant was determined using the Micro BCA kit (Thermo Scientific, USA, Cat. No. 23235). The total protein amount in vaccine formulations was calculated using the following equation.19
Total protein content in formulations = [(theoretical protein content − free protein content)/theoretical protein content] × 100
Stability studies
The vaccine formulations were stored at +4°C for 30 days and periodically examined for macroscopic changes. Antigen content was evaluated on days 0, 15, and 30.
Immunization
Eight-week-old male BALB/c mice were obtained from Kobay Experimental Animal Laboratory (Ankara, Türkiye) and housed under standard laboratory conditions at the same facility (22 ± 2°C, 12 h light/dark cycle) with free access to food and water. A total of five groups of mice were utilized for the study. Each group comprised six mice. The sample size was selected based on previous immunogenicity studies using similar murine vaccination models and ethical considerations aimed at minimizing animal use while ensuring adequate biological replication. No formal a priori sample size calculation was performed. The formulations were administered twice by intramuscular (i.m.) injection at a 14-day interval. Vaccine candidates containing a total antigen concentration of 40 µg/mL and an alum concentration of 2 mg/mL were used for immunizations. Each mouse received 100 µL of the respective vaccine formulation per immunization. This study was reported in accordance with the ARRIVE 2.0 guidelines.
Mice were randomly assigned to five experimental groups (n = 6 per group): PBS control, A29L vaccine formulation, A30L vaccine formulation, A35R vaccine formulation, and A29L+A30L+A35R vaccine formulation.
Blood samples were collected into serum collection tubes 14 days after each immunization. After allowing the blood to clot, samples were centrifuged at 300 × g for 5 min, and the serum was carefully transferred to new tubes and stored at −80°C until ELISA and flow cytometry analyses. Additionally, on day 28, spleen tissues were collected from mice after the second immunization and immediately stored in liquid nitrogen for subsequent RNA extraction and quantitative real-time PCR analysis. Before terminal blood and spleen collection, mice were anesthetized by intramuscular administration of ketamine (200 mg/kg) and xylazine (10 mg/kg). Under deep anesthesia, terminal blood was collected by cardiac puncture, and euthanasia was completed by exsanguination. All procedures were performed in accordance with institutional guidelines and applicable national regulations for the care and use of laboratory animals.
Determination of immune responses
Enzyme-linked immunosorbent assay (ELISA)
The Anti-MPXV IgG Mouse ELISA Kit (Biobyt, Durham, USA; Cat. No. orb1784661), which utilizes A29L as the coating protein, was used to determine IgG concentrations in serum samples from immunized mice. IgG concentrations were calculated based on the assay standard curve and expressed as ng/mL. Additionally, antigen-specific IgG responses were evaluated using a modified protocol based on Law et al. (2005).20 Soluble recombinant Mpox virus (strain Zaire-96-I-16) proteins A29L (ACROBiosystems, Newark, DE, USA; Cat. No. A3L-M5243), A30L (Cat. No. A2L-M52H3), and A35R (Cat. No. A3R-M52H3) expressed in HEK293 cells were purchased from ACROBiosystems (Newark, DE, USA). In short, 100 ng of pure A29L, A30L, and A35R, or BSA (negative control; Sigma-Aldrich, Darmstadt, Germany, Cat. No. A7030) was applied to 96-well plates overnight. After washing, the plates were blocked for 2 hours using 200 μL of 5% dried skim milk in Tris/acetate buffer. Fifty microliters of 1:20 diluted serum samples from immunized mice were added to the plates after washing, and the plates were then incubated for 1 hour and 30 minutes. 50 μL of anti-mouse IgG, HRP-linked antibody (diluted 1:1000; Cell Signaling Technology, Danvers, USA, Cat. No. 7076) was added to the rinsed plates and incubated for 60 minutes. OD450 values were recorded over 60 minutes using a SpectroMax ID3 spectrophotometer outfitted with Softmax Pro 7.1.09 software from Molecular Devices, after 100 μL of substrate (Sigma-Aldrich, Darmstadt, Germany, Cat. No. T0440) was applied.20
Flow cytometry analyses
To quantify cytokine secretion, a flow cytometry-based bead array was used (MU Th cytokine panel 12plex LEGENDplex, BioLegend, San Diego, CA, USA; Cat. No. 741044). Briefly, serum samples of immunized mice were diluted 2-fold with Assay Buffer. Eight dilutions of cytokine standards were prepared. A mixture of 25 μL of beads and 50 μL of serum samples or standards was added into tubes, which were then covered and incubated for 2 hours at 500 rpm on a plate shaker. Following the washing step, 25 µL of detection antibodies was added to each well, and the plates were shaken at 500 rpm for 1 hour. Then, 25 µL of SA-PE was added to each well and incubated for 30 minutes at 500 rpm on a shaker. After the final washing step, samples were analyzed using a FACSCanto II (Becton Dickinson, USA) and LEGENDplexTM software.
Gene expression analysis via RNA extraction and quantitative real-time PCR
RNA extraction was performed following the protocol of the FavorPrepTM Tissue Total RNA Mini Kit (Favorgen, Ping-Tung, Taiwan; Cat. No. FATRK 001). A Nanodrop ND Spectrometer 1000 was used to measure the amount and quality of RNA, and gel electrophoresis on a 1.5% agarose gel was used to confirm the results. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was performed in two steps. Using the iScriptTM Select cDNA Synthesis Kit (Bio-Rad, California, USA, Cat. No. 1708897) and 1 µg of RNA, 5x iScript Select reaction mix, random primers, and iScript reverse transcriptase, reverse transcription reactions were performed. The expression levels of IL-4, IL-6, IL-10, TNF-α, and IFN-γ genes were determined using Real-Time PCR on a Bio-Rad CFX96 Touch Real-Time PCR System. Ct (cycle threshold) values of TNF-α, IFN-γ, IL-4, IL-6, and IL-10 transcripts were normalized to β-actin and adjusted relative to PBS using the 2-∆∆CT method. One-way ANOVA was used to assess if changes in the relative expression levels (REL) of genes were statistically significant. If the P-value of the Dunnett test was less than 0.05, the results were deemed statistically significant.
Results
Characterization of vaccine formulations
The indirect determination method, using a Micro BCA kit, was employed to determine the total protein content in the prepared vaccine formulations. Additionally, the antigen content in the formulations was determined on the 15th and 30th days as part of the stability studies. The results obtained are shown in Table 1. The antigen content of the formulations ranged from 87.61% to 92.47% over the 30-day storage period, indicating that the formulations maintained a high level of antigen content throughout the stability study.
Table 1.
Antigen content of the prepared vaccine formulations. Data are presented as mean ± SD (n = 3).
| Formulations | Antigen content % ± SD |
||
|---|---|---|---|
| Day 0 | Day 15 | Day 30 | |
| Formulation containing A29L | 92.47 ± 0.06 | 91.74 ± 0.03 | 91.59 ± 0.06 |
| Formulation containing A30L | 91.92 ± 0.26 | 89.66 ± 0.02 | 89.52 ± 0.02 |
| Formulation containing A35R | 89.99 ± 0.36 | 89.01 ± 0.02 | 87.81 ± 0.21 |
| Formulation containing A29L+A30L+A35R | 88.49 ± 0.06 | 87.81 ± 0.05 | 87.61 ± 0.06 |
Determination of immunogenicity
Evaluation of antibody responses induced by A29L, A30L, and A35R antigens in a mouse model
To assess the potential of recombinant A29L, A30L, and A35R as antigens for subunit vaccine development, mice were immunized intramuscularly twice, with a 14-day interval between injections. Aluminum hydroxide served as the adjuvant, while the control group received PBS. In the sera of immunized mice, ELISA and flow cytometry were used to measure antigen-specific antibody titers and the immunological profile of cellular responses, such as Th1-related cytokines (TNF-α and IFN-γ) and Th2-related cytokines (IL-4, IL-6, and IL-10). Moreover, at day 28, gene expressions of cytokines were detected by quantitative real-time PCR from spleen tissues of mice immunized with recombinant A29L, A30L, and A35R as antigen in subunit vaccine formulation. Antigen-specific IgG responses were evaluated using two ELISA approaches. First, the Anti-MPXV IgG Mouse ELISA Kit was used to determine IgG concentrations. As shown in Figure 1, IgG against the A29L antigen was detected in mice from the A29L and A29L+A30L+A35R groups after immunization, whereas no detectable response was observed in the PBS control group. A29L-specific IgG concentrations increased significantly after the first immunization, while only a minimal additional increase was observed after the second immunization (Figure 1). No significant differences were observed between the A29L and A29L+A30L+A35R groups. Additionally, no significant changes were observed in mice immunized with the A30L and A35R vaccine formulations compared with the PBS group. Although the kit’s user manual did not provide information on the coating antigen, correspondence with the manufacturer confirmed that A29L was used as the coating protein. Therefore, antibodies specific to A30L and A35R could not be detected using this assay.
Figure 1.

Antigen-specific IgG concentrations in immunized mice. Mice were immunized intramuscularly with alum-adjuvanted recombinant MPXV proteins A29L, A30L, and A35R, individually or in combination. Antigen-specific IgG concentrations were determined using the Anti-MPXV IgG Mouse ELISA Kit based on the assay standard curve and are expressed as ng/mL. The commercial ELISA kit uses A29L as the coating antigen and therefore does not detect antibodies specific to A30L or A35R. Statistical significance was assessed using one-way ANOVA followed by Dunnett’s multiple comparisons test. *p < .05 compared with the PBS control group on Day 14; #p < .05 compared with the PBS control group on Day 28. Data are presented as mean ± SD (n = 6).
Accordingly, the modified protocol of Law et al,20 a total of 100 ng recombinant proteins A29L, A30L, and A35R were used as coating proteins to determine antigen-specific IgG titers. BSA was used as a negative control. The second ELISA result showed that antibodies against A29L, A30L, and A35R antigens were detected in mice from all immunization groups after two immunizations, whereas no antibodies were detected in the control group. IgG titers specific to A29L and A35R antigens significantly increased after the first immunization and continued to rise after the second immunization compared to the control and first immunization IgG titers. IgG titers specific to A30L antigens showed a slight increase after the first immunization, but the second immunization significantly boosted IgG titers, although the increase after the first immunization was not statistically significant. Additionally, the specific IgG titers in the A29L+A30L+A35R groups were higher than those in the A29L, A30L, and A35R groups following both the first and second immunizations (Figure 2).
Figure 2.

Antigen-specific IgG responses to recombinant MPXV proteins. Mice were immunized intramuscularly with alum-adjuvanted recombinant MPXV proteins A29L, A30L, and A35R, individually or in combination. Antigen-specific IgG responses were assessed using a modified protocol based on Law et al.20 Statistical significance was assessed using one-way ANOVA followed by Dunnett’s multiple comparisons test. *p < .05 compared with the PBS control group; #p < .05 compared with Day 14 within the corresponding immunization group. Data are presented as mean ± SD (n = 6).
To evaluate the expressions of Th1-related cytokines (TNF-α and IFN-γ) and Th2-related cytokines (IL-4, IL-6, and IL-10) in the serum of immunized mice, a flow cytometry-based bead array was used. Despite the high antigen-specific IgG titers, serum cytokine levels measured by the flow cytometry-based bead array did not differ significantly among the immunization groups (Supplementary Table). On day 28, the expression levels of TNF-α, IFN-γ, IL-4, IL-6, and IL-10 were evaluated in spleen tissues by quantitative real-time PCR (Figures 3–7). The highest expression level of TNF-α (4.5-fold) was observed in the A30L vaccine formulation administered to the spleens of mice compared to control mice. Additionally, approximately 4-fold increased TNF-α expression level was observed in A29L+A30L+A35R vaccine formulation administered to the spleens of mice (Figure 3). After twice vaccination, IFN-γ expression levels were decreased in all immunization groups compared to the control group mice (Figure 4).
Figure 3.

Relative TNF-α mRNA expression in spleen tissues of immunized mice determined by qRT-PCR. TNF-α mRNA expression was normalized to β-actin and calculated relative to the PBS control group using the 2^−ΔΔCt method. Data are presented as mean ± SD (n = 6). *p < .05 compared with the PBS control group.
Figure 4.

Relative IFN-γ mRNA expression in spleen tissues of immunized mice determined by qRT-PCR. IFN-γ mRNA expression was normalized to β-actin and calculated relative to the PBS control group using the 2^−ΔΔCt method. Data are presented as mean ± SD (n = 6). *p < .05 compared with the PBS control group.
Figure 5.

Relative IL-4 mRNA expression in spleen tissues of immunized mice determined by qRT-PCR. IL-4 mRNA expression was normalized to β-actin and calculated relative to the PBS control group using the 2^−ΔΔCt method. Data are presented as mean ± SD (n = 6). *p < .05 compared with the PBS control group.
Figure 6.

Relative IL-6 mRNA expression in spleen tissues of immunized mice determined by qRT-PCR. IL-6 mRNA expression was normalized to β-actin and calculated relative to the PBS control group using the 2^−ΔΔCt method. Data are presented as mean ± SD (n = 6). *p < .05 compared with the PBS control group.
Figure 7.

Relative IL-10 mRNA expression in spleen tissues of immunized mice determined by qRT-PCR. IL-10 mRNA expression was normalized to β-actin and calculated relative to the PBS control group using the 2^−ΔΔCt method. Data are presented as mean ± SD (n = 6). *p < .05 compared with the PBS control group.
Following the second immunization, IL-4 expression was decreased in the A29L group compared with the PBS control, whereas the other vaccine formulations increased IL-4 expression. The highest IL-4 expression was observed in the trivalent A29L+A30L+A35R group. IL-4 expression increased approximately 9.8-fold, 4.5-fold, and 11-fold in the A30L, A35R, and A29L+A30L+A35R groups, respectively, compared with the PBS control (Figure 5). IL-6 expression was decreased in the A29L and A35R groups compared with the PBS control. The A30L group showed IL-6 expression comparable to that of the PBS control, whereas a significant increase was observed only in the trivalent A29L+A30L+A35R group (Figure 6).
All vaccine formulations except A29L increased IL-10 expression compared with the PBS control. The highest increase was observed in the trivalent A29L+A30L+A35R group (approximately 5.5-fold), while approximately 3.5-fold and 1.8-fold increases were observed in the A30L and A35R groups, respectively (Figure 7). All animals maintained normal activity and body weight throughout the study. No local injection-site reactions, systemic adverse effects, behavioral abnormalities, or mortality were observed during the immunization period.
Discussion
In the present study, recombinant protein-based vaccine formulations containing the MPXV antigens A29L, A30L, and A35R induced robust antigen-specific humoral immune responses in mice, demonstrating the feasibility of these antigens for subunit vaccine development. MPXV exists in two infectious forms, the intracellular mature virion (IMV) and the extracellular enveloped virion (EEV), both of which contribute to viral transmission and pathogenesis.21 IMV is released during cell lysis and is responsible for the transmission of the virus between hosts. The lipid membrane enclosed around IMV forms EEV, which allows the virus to spread effectively within the host’s tissues. Antibodies against these infectious virions are thought to be crucial for immune response, early suppression of viruses, and regulation of viral spread within infected hosts.15 In vivo studies with smallpox demonstrated that antibodies against EEV provide more effective protection than IMV-specific antibodies against lethal challenge.16 Studies performed with vaccinia virus revealed that IMV proteins A27L, L1R, H3L, and D8L have protective antigenicity against disease. Homologues of these proteins in MPXV are A29L, M1R, H3L, and E8L, respectively. Additionally, EEV proteins (A33R and B5R, which are homologues in MPXV and correspond to A35R and B6R) of vaccinia virus are believed to be associated with protective antigenicity.17 Moreover, the A31L protein of variola virus and the homologous protein in vaccinia virus A28L have been evaluated as a target of virus entry into the host, intercellular fusion, and neutralizing antibodies. Homologue of these proteins in MPXV is A30L.18
The selected antigens, A29L, A30L, and A35R, were chosen based on their homology to protective vaccinia and variola virus proteins that have previously been associated with neutralizing antibody responses.22 The current study highlights the potential of recombinant protein-based vaccines targeting both IMV (A29L, A30L) and EEV (A35R) antigens of MPXV. By formulating these proteins with aluminum hydrogel, a strong antigen-specific IgG response was induced, demonstrating the feasibility of a subunit vaccine strategy against MPXV. The individual antigens appeared to contribute differently to the immune response. A29L and A35R induced stronger IgG responses after the first immunization, whereas the A30L response was initially weaker but increased markedly after the booster dose. Notably, A30L induced the highest TNF-α expression among the individual antigen groups, indicating that its immunological contribution may not be captured by antibody titers alone. The trivalent formulation elicited higher antigen-specific IgG responses than any individual formulation and altered the cytokine profile as well; however, because the study was not designed to distinguish additive from synergistic effects, this enhancement is best interpreted as a combined rather than a synergistic effect of the three antigens. Determining the functional contribution of each antigen will require future studies linking antigen composition to neutralizing activity and protective outcomes in challenge models, following the comparative framework used by Belghith et al.23 Importantly, the choice of antigens was based on their high homology with vaccinia and variola viruses, and the present data strengthen the rationale for targeting these proteins in future vaccine designs.
The immunogenicity of the vaccine formulations was evaluated in BALB/c mice following two intramuscular immunizations. The significant increase in antigen-specific IgG responses observed by ELISA supports the immunogenicity of A29L (IMV), A30L (IMV), and A35R (EEV) in the present recombinant protein-based vaccine formulations. Moreover, spleen tissues of mice immunized with vaccine formulations developed in the current study were used to determine the gene expression level of cytokines (IL-4, IL-6, IL-10, TNF-α, and IFN-γ). The results of the present study indicate that vaccine formulation developed with A29L (IMV), A30L (IMV), and A35R (EEV) proteins and alum adjuvant induced a predominantly Th2-biased immune response. In contrast to the changes observed in splenic cytokine gene expression, serum cytokine levels measured by the bead-based flow cytometry assay did not differ significantly among the groups. This discrepancy may reflect the different biological endpoints assessed by the two methods, as qRT-PCR measures cytokine mRNA expression in spleen tissue, whereas the bead-based assay measures circulating cytokine protein concentrations. Thus, changes in local splenic cytokine transcription may not necessarily result in detectable changes in systemic cytokine levels at the same sampling time. Additionally, since serum samples were collected 14 days after the second immunization, transient systemic cytokine responses may have already declined by the time of sampling, as vaccine-induced serum cytokine levels can decrease substantially over time following immunization.24
Previous studies have suggested that severe Mpox infection may be associated with dysregulated cytokine responses and alterations in the Th1/Th2 balance. Th2 response is associated with increased secretion of IL-4, IL-13, IL-5, and IL-6. In severe cases, increased release of IL-10 is an indicator of cytokine storm, which can lead to excessive inflammation. Th1-related cytokines, such as IL-2, TNF-α, IL-12, and IFN-γ, are reduced in level. It is also known that the Th1 pathway is suppressed by an enhanced Th2-related immune response.25,26 Although alum successfully promoted robust antigen-specific humoral responses in the present study, the limited induction of Th1-associated cytokines suggests that alternative adjuvant systems may be required to achieve a more balanced immune response against MPXV.
Neutralizing antibodies and T cell-dependent cytokines are often necessary for the elimination of cytopathic viruses. CD4+ T cells, which generate cytokines like TNF-α and IFN-γ, are crucial for antiviral immune responses.27 MPXV mostly enters the human body through the respiratory system, mucosal membranes, or skin wounds, and it is known that in order to prevent poxvirus infection IFNγ generated by memory CD4+ T is crucial.28 By strengthening antigen presentation to antigen-specific immune cells, adjuvants increase immunogenicity and provide long-term defense against infections. The first adjuvant authorized for clinical use in human vaccines is aluminum. Although aluminum salts provide robust humoral immunity, they generally induce weaker cellular immune responses, which may limit their effectiveness against viral pathogens. It is thought that antigenic targets used in the current study can effectively enhance Th1-related immune response if formulated with TLR agonists such as monophosphoryl lipid A (MPLA), CpG oligodinucleotides, AS01, AS015 (AS01+ CpG), or Alum + CpG in further studies.29,30 Consistent with this idea, a quadrivalent mRNA vaccine targeted A29L, A35R, M1R, and B6R antigens significantly increased MPXV-specific IgG titers compared to the control group mice. Furthermore, Th1-related cellular immunity was increased due to formulation with lipid nanoparticles.31 Similarly, in another mRNA vaccine study targeted M1R, E8L, A29L, A35R, and B6R, consistent with our study, IgG levels were significantly increased after two-dose immunizations, and cellular immunity was also stimulated.32 A29L, M1R, B6R, and A35R proteins, formulated with alum and CpG adjuvants, were observed to increase the level of MPXV-specific IgG, while formulations containing only CpG adjuvant stimulated cellular immunity.17 Additionally, A35, B6, M1, and H3 antigenic targets encapsulated with lipid nanoparticles triggered IgG responses, confirming our results. Also, an A35 antigen-specific Th1-biased cellular response in mice was determined.33
Aluminum salts, such as aluminum hydroxide, aluminum hydroxyl-phosphate sulfate, aluminum potassium phosphate, and others, are the most commonly used adjuvants in human and animal vaccines and elicit strong humoral immune responses triggered by antigen-specific antibodies. With the current study, vaccine candidates developed with both IMV (A29L, A30L) and EEV (A35R) recombinant proteins and aluminum hydrogel significantly increased MPXV-specific IgG level in experimental mice compared to control (p < .05).
Protein subunit vaccines offer notable advantages over live attenuated or viral vector-based platforms. Their non-replicating nature ensures a favorable safety profile, particularly for immunocompromised individuals, while recombinant protein production is cost-effective, scalable, and compatible with existing biomanufacturing systems.34,35 Aluminum salt adjuvants further enhance humoral responses with a long-established safety record.36
Preclinical work on MPXV vaccines has expanded across several platforms, including viral-vectored, mRNA, and multivalent nanoparticle formulations, several of which elicit neutralizing antibodies and confer protection in challenge models.23,37,38 Parallel efforts have pursued non-vaccine strategies as well, from nanomaterial-based antiviral wound dressings to combined detection/photodynamic therapy platforms.39,40 Recombinant protein-based subunit vaccines remain an attractive complement to these approaches: they are non-replicating, allow precise control over antigen composition, and can draw on well-established protein production and adjuvant platforms. In the present study, we evaluated a multivalent recombinant protein formulation combining IMV-derived (A29L, A30L) and EEV-derived (A35R) antigens. Further work, particularly adjuvant optimization and assessment of neutralizing activity and protective efficacy, will be needed to establish the translational potential of this formulation.
Currently, vaccination strategies against Mpox rely on cross-protection conferred by smallpox vaccines, particularly MVA-BN (a non-replicating vaccinia vector), ACAM2000 (a replicating vaccinia vector), and LC16m8 (an attenuated vaccinia strain). These vaccines, while having shown protective efficacy, differ fundamentally from subunit approaches in terms of their platform design, safety profile, and manufacturing requirements, thereby highlighting the potential advantages of recombinant protein-based strategies for Mpox vaccination.
This study has several limitations. First, protective efficacy was not evaluated through viral challenge or neutralization assays. Second, cellular immune responses were assessed using a limited panel of cytokines, without functional T-cell analyses. Finally, the relatively short follow-up period precluded assessment of long-term immune persistence. An additional limitation of this study is the absence of an alum-only control group. Given the well-characterized adjuvant properties of alum, the experimental design primarily focused on evaluating the immunogenicity of the antigen-containing formulations while minimizing animal use in accordance with the 3 R principles. Nevertheless, the lack of an alum-only control group limits the ability to distinguish the independent contribution of alum from the immune responses induced by the antigen-adjuvant formulations. Future studies should include an alum-only control group to further clarify these effects.
Overall, recombinant protein-based vaccine candidates containing A29L, A30L, and A35R induced robust antigen-specific humoral immune responses in mice, supporting the immunogenic potential of these antigens for MPXV subunit vaccine development. Future studies should focus on evaluating neutralizing antibody activity, antigen-specific T-cell responses, protective efficacy in challenge models, and long-term immune persistence, as well as investigating alternative adjuvant systems capable of promoting balanced Th1/Th2 immunity. In addition, reverse vaccinology approaches integrating B-cell, helper T-cell, and cytotoxic T-cell epitopes may provide a complementary strategy for the rational selection and optimization of antigenic targets in future MPXV vaccine development.41
Conclusions
Recombinant protein-based vaccine formulations containing the MPXV antigens A29L, A30L, and A35R induced significant antigen-specific humoral immune responses in mice. These findings provide an immunogenicity proof-of-concept for the use of these antigens in recombinant protein-based MPXV vaccine development. However, the protective potential of the formulations remains to be determined, as neutralizing antibody activity and protection against viral challenge were not evaluated in the present study. Further studies should therefore assess neutralizing antibody responses, protective efficacy in challenge models, antigen-specific cellular immunity, and long-term immune persistence. Optimization of the adjuvant system may also help achieve a more balanced Th1/Th2 immune response.
Supplementary Material
Acknowledgments
The authors thank Prof Dr Serhat Unal and Prof Dr Güneş Esendaglı for valuable scientific discussions and constructive comments. Their support has been greatly appreciated.
Funding Statement
This work was supported by the Health Institutes of Türkiye (TÜSEB) grant [28619].
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Ethics statement
All animal experiments were approved by the KOBAY DHL A.Ş. Local Ethics Committee (Approval No. 642; November 28, 2022) and were conducted in accordance with the applicable national regulations and institutional guidelines for the care and use of laboratory animals. A copy of the ethical approval document is provided as Supplementary File.
Supplementary material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2761828
References
- 1.Netherton CL, Wileman T.. Virus factories, double membrane vesicles and viroplasm generated in animal cells. Curr Opin Virol. 2011;1(5):381–14. doi: 10.1016/j.coviro.2011.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.World Health Organization . Monkeypox ‒ United Kingdom of Great Britain and Northern Ireland [online]. 2022. [accessed 2026 Apr 26]. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381.
- 3.Cabanillas B, Murdaca G, Guemari A, Torres MJ, Azkur AK, Aksoy E, Vitte J, Fernández-Santamaria R, Karavelia A, Castagnoli R, et al. Monkeypox 2024 outbreak: fifty essential questions and answers. Allergy. 2024;79(12):3285–3309. doi: 10.1111/all.16374. [DOI] [PubMed] [Google Scholar]
- 4.Otieno JR, Ruis C, Onoja AB, Kuppalli K, Hoxha A, Nitsche A, Brinkmann A, Michel J, Mbala-Kingebeni P, Mukadi-Bamuleka D, et al. Global genomic surveillance of monkeypox virus. Nat Med. 2025;31(1):342–350. doi: 10.1038/s41591-024-03370-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.World Health Organization . Mpox global strategic preparedness and response plan (SPRP 2024) [online]. 2024. [accessed 2026 Apr 26]. https://cdn.who.int/media/docs/default-source/documents/health-topics/monkeypox/jmo_who_sprpmpox_2024_final_digital.pdf.
- 6.World Health Organization . Mpox outbreak: WHO director-general declares Public Health Emergency of International Concern (PHEIC). 2024. Aug [online]. 14 [accessed 2026 Apr 26]. https://cdn.who.int/media/docs/default-source/documents/health-topics/monkeypox/draft_sprp_mpox_2024.pdf.
- 7.Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, Campos-Outcalt D, Morgan RL, Damon I, Sánchez PJ, et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices — United States, 2022. Morb Mortal Wkly Rep. 2022;71(22):734–742. doi: 10.15585/mmwr.mm7122e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Yang Z. Monkeypox: a potential global threat? J Med Virol. 2022;94(9):4034–4036. doi: 10.1002/jmv.27884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lansiaux E, Jain N, Laivacuma S, Reinis A. The virology of human monkeypox virus (hMPXV): a brief overview. Virus Res. 2022;322:198932. doi: 10.1016/j.virusres.2022.198932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.World Health Organization . Mpox vaccines: questions and answers [online]. 2024. [accessed 2026 Apr 26]. https://www.who.int/news-room/questions-and-answers/item/mpox-vaccines.
- 11.McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58(2):260–267. doi: 10.1093/cid/cit703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, Djingarey MH, Olson V, Damon IK, Khalakdina A. Emergence of monkeypox — west and Central Africa, 1970–2017. Morb Mortal Wkly Rep. 2018;67(10):306–310. doi: 10.15585/mmwr.mm6710a5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Reynolds MG, McCollum AM, Nguete B, Lushima RS, Petersen BW. Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017;9(12):380. doi: 10.3390/v9120380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Xiao YH, Zeng YH, Schante C, Joshi SB, Buchman GW, Volkin DB, Middaugh CR, Isaacs SN. Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus. Vaccine. 2020;38(38):6007–6018. doi: 10.1016/j.vaccine.2020.07.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Pickup DJ. Extracellular virions: the advance guard of poxvirus infections. PLoS Pathog. 2015;11(7):e1004904. doi: 10.1371/journal.ppat.1004904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Putz MM, Midgley CM, Law M, Smith GL. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med. 2006;12(11):1310–1315. doi: 10.1038/nm1457. [DOI] [PubMed] [Google Scholar]
- 17.Yang X, Yang X, Du S, Hu C, Yang X, Wang X, Hu X, Rcheulishvili N, Wang PG, Lin J. A subunit vaccine candidate composed of Mpox virus A29L, M1R, A35R, and B6R elicits robust immune response in mice. Vaccines (Basel). 2023;11(9):1420. doi: 10.3390/vaccines11091420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Papukashvili D, Rcheulishvili N, Liu C, Wang X, He Y, Wang PG. Strategy of developing nucleic acid-based universal monkeypox vaccine candidates. Front Immunol. 2022;13:1050309. doi: 10.3389/fimmu.2022.1050309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cheng YJ, Huang CY, Ho HM, Huang MH. Morphology and protein adsorption of aluminum phosphate and aluminum hydroxide and their potential catalytic function in the synthesis of polymeric emulsifiers. Colloids Surf Physicochem Eng Asp. 2021;608:125564. doi: 10.1016/j.colsurfa.2020.125564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Law M, Putz MM, Smith GL. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gener Virol. 2005;86(Pt 4):991–1000. doi: 10.1099/vir.0.80660-0. [DOI] [PubMed] [Google Scholar]
- 21.Melendez JA, Sun H, Bonner J, Chen Q. Characterization of a plant-derived monoclonal antibody targeting extracellular enveloped virions of Monkeypox virus. Front Plant Sci. 2024;15:1481452. doi: 10.3389/fpls.2024.1481452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Sig Transduct Target Ther. 2022;7(1):373. doi: 10.1038/s41392-022-01215-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Belghith AA, Cotter CA, Ignacio MA, Earl PL, Hills RA, Howarth MR, Yee DS, Brenchley JM, Moss B. Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates. Nat Commun. 2025;16(1):4726. doi: 10.1038/s41467-025-59826-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Dehghan M, Askari H, Tohidfar M, Ranaei Siadat SO, Fatemi F. Improvement of RBD-FC immunogenicity by using alum–sodium alginate adjuvant against SARS-CoV-2. Influenza Resp Viruses. 2024;18(11):e70018. doi: 10.1111/irv.70018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.da Silva GB, de Carvalho Braga G, Simoes JLB, Kempka AP, Bagatini MD. Cytokine storm in human monkeypox: a possible involvement of purinergic signaling. Cytokine. 2024;177:156560. doi: 10.1016/j.cyto.2024.156560. [DOI] [PubMed] [Google Scholar]
- 26.Johnston SC, Johnson JC, Stonier SW, Lin KL, Kisalu NK, Hensley LE, Rimoin AW. Cytokine modulation correlates with severity of monkeypox disease in humans. J Clin Virol. 2015;63:42–45. doi: 10.1016/j.jcv.2014.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Agrati C, Cossarizza A, Mazzotta V, Grassi G, Casetti R, De Biasi S, Pinnetti C, Gili S, Mondi A, Cristofanelli F, et al. Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study. Lancet Infect Dis. 2023;23(3):320–330. doi: 10.1016/S1473-3099(22)00662-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Harbour JC, Abdelbary M, Schell JB, Fancher SP, McLean JJ, Nappi TJ, Liu S, Nice TJ, Xia Z, Früh K, et al. T helper 1 effector memory CD4+ T cells protect the skin from poxvirus infection. Cell Rep. 2023;42(5):112407. doi: 10.1016/j.celrep.2023.112407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wang ZB, Xu J. Better adjuvants for better vaccines: progress in adjuvant delivery systems, modifications, and adjuvant–antigen codelivery. Vaccines. 2020;8(1):128. doi: 10.3390/vaccines8010128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gursel M, Gursel I. Development of CpG ODN based vaccine adjuvant formulations. Methods Mol Biol. 2016;1404:289–298. doi: 10.1007/978-1-4939-3389-1_20. [DOI] [PubMed] [Google Scholar]
- 31.Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H, Long J, Cao Y, Mai J, Miao Y, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Sig Transduct Target Ther. 2023;8(1):172. doi: 10.1038/s41392-023-01432-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Zhang RR, Wang ZJ, Zhu YL, Tang W, Zhou C, Zhao S-Q, Wu M, Ming T, Deng Y-Q, Chen Q, et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerging Microbes Infections. 2023;12(1):2192815. doi: 10.1080/22221751.2023.2192815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu YJ, Palowitch GM, Dokic A, Sanchez-Velazquez R, Schlatterer K, Sarkar S, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024;187(6):1363–1373.e12. doi: 10.1016/j.cell.2024.01.017. [DOI] [PubMed] [Google Scholar]
- 34.Travieso T, López-García A, Reyes-Sandoval A. The use of viral vectors in vaccine development. NPJ Vaccin. 2022;7(1):75. doi: 10.1038/s41541-022-00477-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bayani F, Shokri S, Darazam IA, Marjani M. An overview of the vaccine platforms to combat COVID-19. Clin Exp Vaccin Res. 2023;12(1):1–12. doi: 10.7774/cevr.2023.12.1.1. [DOI] [Google Scholar]
- 36.Laera D, Aruta MG, Vitiello G, Mastrangelo D, Rea G. Aluminum adjuvants—“Back to the future”. Pharmaceutics. 2023;15(7):1884. doi: 10.3390/pharmaceutics15071884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Jacob-Dolan C, Ty D, Hope D, McMahan K, Liu J, Powers OC, Cotter CA, Sciacca M, Wu C, Borducchi E, et al. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Sci Transl Med. 2024;16(740):eadl4317. doi: 10.1126/scitranslmed.adl4317. [DOI] [PubMed] [Google Scholar]
- 38.Ye Q, Zhang D, Zhang RR, Xu Q, Huang XY, Huang B, Sun M-X, Cong Z, Zhu L, Ma J, et al. A penta-component mpox mRNA vaccine induces protective immunity in nonhuman Primates. Nat Commun. 2024;15(1):10611. doi: 10.1038/s41467-024-54909-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wang W, Li M, Liu Z, Chen J, Liu K, Wei F, Li J, Xie Y, Jiang Y, Hoshino T, et al. Nano-silver-selenium liquid dressing facilitates treatment of Monkeypox and prevention of viral transmission in a surrogate mouse model. Exploration. 2026;6(3):20240253. doi: 10.1002/EXP.20240253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Wang W, Liu Z, Li M, Zheng J, Zhang R, Liu K, Li X, Wen S, Yu J, Pan M, et al. Aiegen-based proactive early warning system and precise treatment strategy for Monkeypox prevention and control. Adv Sci. 2026;13(9):e15865. doi: 10.1002/advs.202515865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Afnani MR, Emilia NF, Nurlaili E, Rovik A, Ansori ANM, Parikesit AA, Chatterjee S, Mahata J, Firdous A, Sahadewa S, et al. In silico design of a multi-epitope rabies vaccine candidate incorporating African HLA diversity: a reverse vaccinology approach. Narra X. 2026;4(1):e263. doi: 10.52225/narrax.v4i1.263. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
